Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Phase 2TerminatedNCT00600093

Rabin Medical Center20 enrolled

Overview

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Parkinson Disease Perioperative Care

Interventions

AmantadineDRUG

IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a diagnosis of Parkinson Disease refered for surgery at our institution. Exclusion Criteria: * Cardiac and neurosurgical procedures * Inability to sign informed Consent * allergy to Amantadine * Congestive heart failure * Arrythmia (including bradycardia below 55 bpm) * renal failure (creatinin above 1.5) * If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Locations (1)

Rabin Medical Center

Petah Tikva, Israel

Outcomes

Primary Outcomes

Mortality, Surgical site infection, Pneumonia, Myocardial Infarction, Cerebral Vascular Accident (CVA).

Time frame: 28 days

Secondary Outcomes

UPDRS score

Time frame: 2,28 days

Pain (vas score), Analgetic drugs requirement

Time frame: 2 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.